Viracta Therapeutics IncNASDAQ:VIRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2238
- TODAY'S CHANGE (%)-0.0006 (-0.2674%)
- Bid / Lots0.2220/ 49
- Ask / Lots0.2498/ 25
- Open / Previous Close0.2200 / 0.2244
- Day Range
- 52 Week Range
- Volume206,924
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VIRX |
|---|---|---|
| 09:32 ET | 46712 | 0.2244 |
| 09:34 ET | 7298 | 0.2288 |
| 09:36 ET | 1400 | 0.2285 |
| 09:38 ET | 400 | 0.2288 |
| 09:39 ET | 1000 | 0.2245 |
| 09:43 ET | 500 | 0.2288 |
| 09:45 ET | 550 | 0.22 |
| 09:48 ET | 100 | 0.221 |
| 09:50 ET | 11400 | 0.22 |
| 09:59 ET | 250 | 0.2282 |
| 10:01 ET | 10000 | 0.2201 |
| 10:21 ET | 23193 | 0.219988 |
| 10:26 ET | 698 | 0.218971 |
| 10:28 ET | 500 | 0.2188 |
| 10:30 ET | 2853 | 0.2107 |
| 10:32 ET | 3600 | 0.2147 |
| 10:33 ET | 400 | 0.21662 |
| 10:37 ET | 100 | 0.2147 |
| 10:42 ET | 500 | 0.2186 |
| 10:53 ET | 100 | 0.2147 |
| 10:55 ET | 6100 | 0.2185 |
| 10:57 ET | 400 | 0.2186 |
| 11:00 ET | 100 | 0.218599 |
| 11:24 ET | 2539 | 0.2185 |
| 11:40 ET | 600 | 0.2185 |
| 11:42 ET | 150 | 0.2236 |
| 11:49 ET | 400 | 0.2236 |
| 12:18 ET | 100 | 0.222 |
| 12:20 ET | 1000 | 0.222101 |
| 12:23 ET | 1650 | 0.223 |
| 12:27 ET | 100 | 0.223 |
| 12:34 ET | 500 | 0.2246 |
| 12:38 ET | 1000 | 0.228799 |
| 12:50 ET | 540 | 0.222 |
| 12:54 ET | 1000 | 0.2244 |
| 01:03 ET | 100 | 0.225 |
| 01:06 ET | 5900 | 0.2235 |
| 01:10 ET | 200 | 0.2255 |
| 01:42 ET | 246 | 0.22201 |
| 01:53 ET | 1200 | 0.2244 |
| 02:09 ET | 177 | 0.2233 |
| 02:22 ET | 132 | 0.2254 |
| 02:31 ET | 775 | 0.226 |
| 02:36 ET | 201 | 0.2264 |
| 02:38 ET | 885 | 0.2257 |
| 02:42 ET | 8210 | 0.2233 |
| 02:44 ET | 279 | 0.2234 |
| 03:00 ET | 2300 | 0.22505 |
| 03:12 ET | 1324 | 0.225 |
| 03:14 ET | 500 | 0.2259 |
| 03:16 ET | 301 | 0.2268 |
| 03:18 ET | 7110 | 0.226 |
| 03:20 ET | 3743 | 0.226 |
| 03:23 ET | 400 | 0.2267 |
| 03:36 ET | 100 | 0.2233 |
| 03:39 ET | 100 | 0.2233 |
| 03:43 ET | 510 | 0.2233 |
| 03:48 ET | 100 | 0.2233 |
| 03:52 ET | 2100 | 0.2233 |
| 03:54 ET | 4171 | 0.22 |
| 03:56 ET | 200 | 0.22 |
| 03:57 ET | 826 | 0.22 |
| 03:59 ET | 23920 | 0.2238 |
Sep 3, 2024
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference, from 7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
7:00AM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Viracta Therapeutics Inc | 8.8M | -0.2x | --- |
Calidi Biotherapeutics Inc | 8.8M | -0.2x | --- |
Carmell Corp | 8.6M | -0.3x | --- |
Portage Biotech Inc | 9.1M | -0.1x | --- |
Silexion Therapeutics Corp | 8.5M | -6.2x | --- |
Mustang Bio Inc | 8.3M | -0.1x | --- |
Company Information
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated in multiple ongoing clinical trials, including a pivotal, global, multicenter, open-label Phase II basket trial for the treatment of multiple subtypes of relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) lymphoma (NAVAL-1), as well as a multinational, open-label Phase Ib/II clinical trial for the treatment of patients with recurrent or metastatic (R/M) EBV + nasopharyngeal carcinoma (NPC) and other advanced EBV + solid tumors. The Company is also pursuing the application of its Kick and Kill approach in other virus-related cancers.
Contact Information
- Headquarters
- 2533 S COAST HWY 101, SUITE 210CARDIFF BY THE SEA, CA, United States 92007
- Phone
- 858-400-8470
- Fax
- 650-266-3501
Executives
- Independent Chairman of the Board
- Roger Pomerantz
- President, Chief Executive Officer, Director
- Mark Rothera
- Chief Financial Officer
- Michael Faerm
- Senior Vice President - Finance
- Melody Burcar
- Chief Medical Officer
- Darrel Cohen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 39.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.69 |
EPS | $-1.16 |
Book Value | $0.47 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
